A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2

Journal of Virology

Volumn 89, Issue 8, 2015, Pages 4676-4680

  Goujon, Caroline ^a,b   Greenbury, Rebecca A ^a   Papaioannou, Stelios ^a   Doyle, Tomas ^a   Malim, Michael H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; MYXOVIRUS RESISTANCE PROTEIN; PROTEIN MX2; UNCLASSIFIED DRUG; MX2 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR GENETICS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; VIRUS INHIBITION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOBLOTTING; METABOLISM; POLYMERIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORTHOMYXOVIRIDAE;

AMINO ACID MOTIFS; ARGININE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HIV-1; HUMANS; IMMUNOBLOTTING; MOLECULAR SEQUENCE DATA; MYXOVIRUS RESISTANCE PROTEINS; POLYMERIZATION;

EID: 84925424677     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00169-15     Document Type: Article

References (27)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975-990. http://dx.doi.org/10.1038/nrd2422.
2. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89:1-47. http://dx.doi.org/10.1099/vir.0.83391-0.
3. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1:519-525. http://dx.doi.org/10.1016/j.coviro.2011.10.008.
4. Haller O, Kochs G. 2011. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 31:79-87. http://dx.doi.org/10.1089/jir.2010.0076.
5. Haller O, Staeheli P, Schwemmle M, Kochs G. 5 January 2015. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol http://dx.doi.org/10.1016/j.tim.2014.12.003.
6. Kim BH, Shenoy AR, Kumar P, Bradfield CJ, MacMicking JD. 2012. IFN-inducible GTPases in host cell defense. Cell Host Microbe 12:432-444. http://dx.doi.org/10.1016/j.chom.2012.09.007.
7. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, Schaller T, Hué S, Barclay WS, Schulz R, Malim MH. 2013. Human MX2 is an interferoninduced post-entry inhibitor of HIV-1 infection. Nature 502:559-562. http://dx.doi.org/10.1038/nature12542.
8. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, Cen S, Guo F, Liang C. 2013. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14:398-410. http://dx.doi.org/10.1016/j.chom.2013.08.015.
9. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD. 2013. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502: 563-566. http://dx.doi.org/10.1038/nature12653.
10. Gao S, von der Malsburg A, Dick A, Faelber K, Schröder GF, Haller O, Kochs G, Daumke O. 2011. Structure of myxovirus resistance protein a reveals intraand intermolecular domain interactions required for the antiviral function. Immunity 35:514-525. http://dx.doi.org/10.1016/j.immuni.2011.07.012.
11. Mitchell PS, Patzina C, Emerman M, Haller O, Malik HS, Kochs G. 2012. Evolution-guided identification of antiviral specificity determinants in the broadly acting interferon-induced innate immunity factor MxA. Cell Host Microbe 12:598-604. http://dx.doi.org/10.1016/j.chom.2012.09.005.
12. Rennie ML, McKelvie SA, Bulloch EM, Kingston RL. 2014. Transient dimerization of human MxA promotes GTP hydrolysis, resulting in a mechanical power stroke. Structure 22:1433-1445. http://dx.doi.org/10.1016/j.str.2014.08.015.
13. Goujon C, Moncorgé O, Bauby H, Doyle T, Barclay WS, Malim MH. 2014. Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. J Virol 88:9017-9026. http://dx.doi.org/10.1128/JVI.01269-14.
14. Fribourgh JL, Nguyen HC, Matreyek KA, Alvarez FJ, Summers BJ, Dewdney TG, Aiken C, Zhang P, Engelman A, Xiong Y. 2014. Structural insight into HIV-1 restriction by MxB. Cell Host Microbe 16:627-638. http://dx.doi.org/10.1016/j.chom.2014.09.021.
15. Buffone C, Schulte B, Opp S, Diaz-Griffero F. 7 January 2015. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction. J Virol http://dx.doi.org/10.1128/JVI.03730-14.
16. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, Strouvelle VP, Zang TM, Willett BJ, Boutell C, Bieniasz PD, Wilson SJ. 2014. Host and viral determinants of Mx2 antiretroviral activity. J Virol 88:7738-7752. http://dx.doi.org/10.1128/JVI.00214-14.
17. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, Brandariz-Nuñez A, Diaz-Griffero F. 2014. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology 11:68. http://dx.doi.org/10.1186/PREACCEPT-6453674081373986.
18. Matreyek KA, Wang W, Serrao E, Singh P, Levin HL, Engelman A. 2014. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology 11:90. http://dx.doi.org/10.1186/s12977-014-0090-z.
19. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267. http://dx.doi.org/10.1126/science.272.5259.263.
20. Best S, Le Tissier P, Towers G, Stoye JP. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382:826-829. http://dx.doi.org/10.1038/382826a0.
21. Bock M, Bishop KN, Towers G, Stoye JP. 2000. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 74:7422-7430. http://dx.doi.org/10.1128/JVI.74.16.7422-7430.2000.
22. Jolicoeur P, Baltimore D. 1976. Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses. Proc Natl Acad Sci USA 73:2236-2240. http://dx.doi.org/10.1073/pnas.73.7.2236.
23. Pryciak PM, Varmus HE. 1992. Fv-1 restriction and its effects on murine leukemia virus integration in vivo and in vitro. J Virol 66:5959-5966.
24. Bishop KN, Mortuza GB, Howell S, Yap MW, Stoye JP, Taylor IA. 2006. Characterization of an amino-terminal dimerization domain from retroviral restriction factor Fv1. J Virol 80:8225-8235. http://dx.doi.org/10.1128/JVI.00395-06.
25. Harbury PB, Zhang T, Kim PS, Alber T. 1993. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401-1407. http://dx.doi.org/10.1126/science.8248779.
26. Harbury PB, Kim PS, Alber T. 1994. Crystal structure of an isoleucinezipper trimer. Nature 371:80-83. http://dx.doi.org/10.1038/371080a0.
27. Jarrosson-Wuilleme L, Goujon C, Bernaud J, Rigal D, Darlix JL, Cimarelli A. 2006. Transduction of nondividing human macrophages with gammaretrovirus-derived vectors. J Virol 80:1152-1159. http://dx.doi.org/10.1128/JVI.80.3.1152-1159.2006.